- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Cladribine Tablets: A Review in Relapsing MS ; volume:33 ; number:2 ; day:30 ; month:1 ; year:2019 ; pages:193 ; date:2.2019
CNS drugs ; 33, Heft 2 (30.1.2019), 193, 2.2019
- Urheber
-
Deeks, Emma D.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-019-00604-8
- URN
-
urn:nbn:de:101:1-2019031219282046340979
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Deeks, Emma D.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
Review on Tablet in Tablet techniques
Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
Endocarditis following ocrelizumab in relapsing-remitting MS
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
Review on Tablet in Tablet techniques
Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
Endocarditis following ocrelizumab in relapsing-remitting MS
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates
Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis
Review on Tablet in Tablet techniques
Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
Cladribine Tablets and Relapsing–Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know
Endocarditis following ocrelizumab in relapsing-remitting MS
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study
Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates